ClinicalTrials.gg

Program

KIF18A Inhibitor MEN2501

Its studies are mostly in Ovarian Neoplasms, led by Menarini Group.

Furthest: phase 1, since Nov 6, 20251 company-led study, 1 open or runningNext primary completion: Dec 2, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Menarini Group11 open or runningphase 1since Nov 6, 2025Nov 6, 2025Dec 2, 2027phase 1 · NCT07226427

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 6, 2025First study: phase 1 study in Ovarian NeoplasmsFirst studyNCT07226427 · 100 planned · United States, Australia, Spain

Ahead

  1. Dec 2, 2027Primary completion: phase 1 study in Ovarian NeoplasmsNCT07226427

TargetBeta

KIF18A →read by rule
“An orally bioavailable inhibitor of the human kinesin-like protein KIF18A, ”NCIt, by rule

Other programs on KIF18A

ProgramCompanyFurthest phaseStudies
KIF18A Inhibitor ATX-295ruleaccent-therapeuticsphase 21

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07226427Ovarian Neoplasms · United States, Australia, Spain1RecruitingDec 2, 2027100

How it is read

Names in the registry

  • “MEN2501”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.